专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06420413B2 Heterocycloalkylbenzocyclobutane and heteroarylbenzocyclobutane compounds 失效
标题翻译：杂环烷基苯并环丁烷和杂芳基苯并环丁烷化合物
公开(公告)号：US06420413B2
公开(公告)日：2002-07-16
申请号：US09833827
申请日：2001-04-12
申请人： Jean-Louis Peglion , Aimée Dessinges , Bertrand Goument , Mark Millan , Françoise Lejeune , Mauricette Brocco
发明人： Jean-Louis Peglion , Aimée Dessinges , Bertrand Goument , Mark Millan , Françoise Lejeune , Mauricette Brocco
IPC分类号： C07D20970
CPC分类号： C07D407/12 , C07C215/42 , C07D209/16 , C07D209/40 , C07D307/93 , C07D317/70 , C07D319/14 , C07D333/78
摘要： A compound selected from those of formula (I): wherein: denotes single bond or double bond, n is integer from 1 to 6 inclusive, R1, and R2 represent a group selected from hydrogen, linear or branched (C1-C6)-alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, and heteroarylalkyl, X represents a group selected from —CH═CH—, oxygen, S(O)m wherein m is integer from 0 to 2 inclusive, and NR3 wherein R3 represents a group as defined in the description, Y represents CH or CH2 depending on whether denotes single bond or double bond, or may have the additional meaning of oxygen when X represents oxygen, T represents monocyclic or polycyclic (C3-C10)cycloalkyl optionally containing within the ring system oxygen, selenium, S(O)p, NR3, or SiR4R5 wherein p, R3, R4, and R5 are as defined in the description, its isomers and addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal products containing the same are useful in the treatment of CNS disorders.
摘要翻译：选自式（I）的化合物：其中：表示单键或双键，n为1〜6的整数，R1和R2表示选自氢，直链或支链（C1-C6） - 烷基，芳基，芳基烷基，环烷基，环烷基烷基，烯基，炔基，杂环烷基，杂环烷基烷基，杂芳基和杂芳基烷基，X表示选自-CH = CH-，氧，S（O）m的基团，其中m为0至2的整数和NR 3，其中R 3表示说明书中定义的基团，Y表示CH或CH 2，取决于是单键或双键，或当X表示氧时，可以具有氧的额外含义，T表示单环或多环（C 3 -C 10 ）环烷基，其任选地在环体系内含有氧，硒，S（O）p，NR 3或SiR 4 R 5，其中p，R 3，R 4和R 5如说明书中所定义，其异构体及其加成盐与药学上可接受的酸或碱，以及含有其的药物可用于治疗CNS疾病。

2. 发明授权

US07465733B2 Piperazine compounds 失效
标题翻译：哌嗪化合物
公开(公告)号：US07465733B2
公开(公告)日：2008-12-16
申请号：US11395747
申请日：2006-03-31
申请人： Jean-Louis Peglion , Aimée Dessinges , Bertrand Goument , Mark Millan , Clotilde Mannoury La Cour
发明人： Jean-Louis Peglion , Aimée Dessinges , Bertrand Goument , Mark Millan , Clotilde Mannoury La Cour
IPC分类号： A61K31/495 , A61K31/496 , C07D295/096 , C07D215/08 , C07D311/68 , C07D319/08 , A61K31/551
CPC分类号： C07D313/08 , C07D211/22 , C07D213/81 , C07D215/42 , C07D243/08 , C07D249/12 , C07D295/096 , C07D295/155 , C07D311/68 , C07D319/20 , C07D405/04
摘要： A compound selected from those of formula (I): wherein: R1, R2, R3 and R4, which may be the same or different, each represent an atom or group selected from hydrogen, halogen, alkyl, alkoxy, phenyl and cyano, X represents a bond, an oxygen atom or a group selected from —(CH2)m—, —OCH2— and —NR5—, wherein m represents 1 or 2, and R5 is as defined in the description, Y represents an oxygen atom or a group selected from NR7 and CHR8, wherein R7 and R8 are as defined in the description, Z represents a nitrogen atom or a CH group, n represents 1 or 2, Ak represents an alkylene chain, Ar represents an aryl or heteroaryl group, its optical isomers, and addition salts thereof with a pharmaceutically acceptable acid. Medical products containing the same which are useful in the treatment of conditions requiring a serotonin reuptake inhibitor and/or NK1 antagonist.
摘要翻译：选自式（I）的化合物：其中：R 1，R 2，R 3和R 4可以相同或不同，表示选自氢，卤素，烷基，烷氧基，苯基和氰基的原子或基团，X 表示键，氧原子或选自 - （CH 2）m - ， - OCH 2 - 和-NR 5 - 的基团，其中m表示1或2，R 5如说明书中所定义，Y表示氧原子或选自NR7和CHR8的基团，其中R7和R8如说明书中所定义，Z表示氮原子或CH基团，n表示1或2，Ak表示亚烷基链，Ar表示芳基或杂芳基，其光学异构体及其与药学上可接受的酸的加成盐。含有该药物的药物可用于治疗需要5-羟色胺再摄取抑制剂和/或NK1拮抗剂的病症。

3. 发明授权

US06486171B2 Piperidine compounds 失效
标题翻译：哌啶化合物
公开(公告)号：US06486171B2
公开(公告)日：2002-11-26
申请号：US10105171
申请日：2002-03-25
申请人： Jean-Louis Peglion , Aimée Dessinges , Christophe Poitevin , Mark Millan , Anne Dekeyne
发明人： Jean-Louis Peglion , Aimée Dessinges , Christophe Poitevin , Mark Millan , Anne Dekeyne
IPC分类号： C07D47104
CPC分类号： C07D471/04 , C07D491/04 , C07D495/04
摘要： A compound selected from those of formula (I): wherein: W represents optionally substituted naphthyl, or a group of formula Y (wherein) as defined in the description, n represents an integer from 1 to 6 inclusive, Z represents a single bond, oxygen, or optionally substituted nitrogen, A and Q each represent CH or nitrogen, it being understood that A or Q must be N and the other CH, M, together with a carbon of the phenyl to which it is bonded, represents thienyl, furyl, pyrrolyl, or oxopyrrolyl, its isomers, and pharmaceutically-acceptable acid or base addition salts thereof, and medicinal products containing the same, which are useful in the treatment of some CNS disorders.
摘要翻译：选自式（I）的化合物：其中：W表示任选取代的萘基，或如说明书中所定义的式Y（其中）的基团，n表示1至6的整数，Z表示单键，氧或任选取代的氮，A和Q各自表示CH或氮，应理解A或Q必须为N，另一个CH，M与其所键合的苯基的碳一起代表噻吩基，呋喃基，吡咯基或氧代吡咯基，其异构体及其药学上可接受的酸或碱加成盐，以及含有它们的药物，其可用于治疗一些CNS障碍。

4. 发明授权

US06399616B1 Pyridine compounds 失效
标题翻译：吡啶化合物
公开(公告)号：US06399616B1
公开(公告)日：2002-06-04
申请号：US09641777
申请日：2000-08-18
申请人： Jean-Louis Peglion , Aimée Dessinges , Christophe Poitevin , Mark Millan , Anne Dekeyne
发明人： Jean-Louis Peglion , Aimée Dessinges , Christophe Poitevin , Mark Millan , Anne Dekeyne
IPC分类号： A61K31496
CPC分类号： C07D471/04 , C07D491/04 , C07D495/04
摘要： A compound selected from those of formula (I): wherein: W represents optionally substituted naphthyl, n represents an integer from 2 to 3 inclusive, Z represents a single bond, A represents nitrogen, Q represents nitrogen, M, together with the carbon of pyridyl to which it is bonded, represents thieno, furo, pyrrolo or oxopyrrolo, Its optical isomers and pharmaceutically-acceptable acid or base additional salts thereof, and Medicinal products containing the same which are useful in the treatment of CNS disorders. It being understood that “aryl” is phenyl, naphthyl, dihydronaphthyl, or tetrahydronaphthyl.
摘要翻译：选自式（I）的化合物：其中：W表示任选取代的萘基，n表示2〜3的整数，Z表示单键，A表示氮，Q表示氮，M表示与吡咯基，吡咯基或氧吡咯，其光学异构体和药学上可接受的酸或碱的另外的盐，和含有它们的可用于治疗CNS病症的药物。可以理解的是“ 芳基“是苯基，萘基，二氢萘基或四氢萘基。

5. 发明申请

US20100249397A1 Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid 有权
公开(公告)号：US20100249397A1
公开(公告)日：2010-09-30
申请号：US12798042
申请日：2010-03-29
申请人： Jean-Louis Peglion , Aimée Dessinges , Bernard Serkiz
发明人： Jean-Louis Peglion , Aimée Dessinges , Bernard Serkiz
IPC分类号： C07D223/16
CPC分类号： C07D223/16
摘要： Process for the synthesis of ivabradine of formula (I): and addition salts thereof with a pharmaceutically acceptable acid.

6. 发明申请

US20100160628A1 Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid 有权
标题翻译：将伊伐布拉德及其加成盐与药学上可接受的酸合成的方法
公开(公告)号：US20100160628A1
公开(公告)日：2010-06-24
申请号：US12655087
申请日：2009-12-23
申请人： Jean-Louis Peglion , Aimée Dessinges , Bernard Serkiz , Jean-Michel Lerestif , Jean-Pierre Lecouve
发明人： Jean-Louis Peglion , Aimée Dessinges , Bernard Serkiz , Jean-Michel Lerestif , Jean-Pierre Lecouve
IPC分类号： C07D223/16 , C07C47/47
CPC分类号： C07D223/16
摘要： Process for the synthesis of ivabradine of formula (I): and addition salts thereof with a pharmaceutically acceptable acid.
摘要翻译：用于合成式（I）的伊伐布拉定的方法及其与药学上可接受的酸的加成盐。

7. 发明申请

US20100249398A1 Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid 有权
公开(公告)号：US20100249398A1
公开(公告)日：2010-09-30
申请号：US12798048
申请日：2010-03-29
申请人： Jean-Louis Peglion , Aimée Dessinges , Bernard Serkiz
发明人： Jean-Louis Peglion , Aimée Dessinges , Bernard Serkiz
IPC分类号： C07D223/16
CPC分类号： C07D223/16
摘要： Process for the synthesis of ivabradine of formula (I):and addition salts thereof with a pharmaceutically acceptable acid.

8. 发明授权

US06323217B2 Piperidine-4 sulphonamide compounds 失效
标题翻译：哌啶-4-磺酰胺化合物
公开(公告)号：US06323217B2
公开(公告)日：2001-11-27
申请号：US09772569
申请日：2001-01-30
申请人： Jean-Louis Peglion , Aimée Dessinges , Christophe Poitevin , Jean-Paul Vilaine , Nicole Villeneuve , Catherine Thollon , Marie-Pierre Bourguignon
发明人： Jean-Louis Peglion , Aimée Dessinges , Christophe Poitevin , Jean-Paul Vilaine , Nicole Villeneuve , Catherine Thollon , Marie-Pierre Bourguignon
IPC分类号： A61K314725
CPC分类号： C07D401/12 , C07D405/06 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D491/04 , C07D495/04
摘要： A compound of formula (I): wherein: R1 represents hydrogen or alkyl, R2a and R2b represent a group selected from hydrogen, halogen, alkyl, hydroxy, alkoxy, trihaloalkyl, cyano, nitro, amino, alkylamino and dialkylamino, R3 represents hydrogen or hydroxy, X represents oxygen or methylene, V represents an alkylene chain that is optionally unsaturated and optionally substituted, U represents a bond or an alkylene chain, W represents a group selected from aryl and heteroaryl, each of those groups being optionally substituted by one or more identical or different groups, its isomers, its hydrates, its solvates and addition salts thereof with a pharmaceutically acceptable acid. Medicinal products containing the same which are useful in the treatment of diseases or pathological conditions in which endothelial dysfunction is known.
摘要翻译：式（I）化合物：其中：R 1表示氢或烷基，R 2a和R 2b表示选自氢，卤素，烷基，羟基，烷氧基，三卤代烷基，氰基，硝基，氨基，烷基氨基和二烷基氨基的基团，R 3表示氢或羟基，X表示氧或亚甲基，V表示任选不饱和且任选取代的亚烷基链，U表示键或亚烷基链，W表示选自芳基和杂芳基的基团，这些基团中的每一个可任选地被一个或多个更多相同或不同的基团，其异构体，其水合物，其溶剂合物及其与药学上可接受的酸的加成盐。含有该药物的药物可用于治疗已知内皮功能障碍的疾病或病理状况。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式